中國巨石(600176.SH):擬投建年產15萬噸玻璃纖維短切原絲生產線建設項目
格隆匯2月8日丨中國巨石(600176.SH)公佈,為進一步優化公司產品結構,提高盈利能力,公司擬在成都智能製造生產基地投資建設年產15萬噸玻璃纖維短切原絲生產線建設項目。
項目建設週期1年,計劃於2022年上半年開工建設;項目總投資179758.83萬元,資金來源為公司自籌及銀行貸款。
項目建成後,預計每年可實現銷售收入9億元,年平均利潤總額38348.13萬元(上述數據僅為公司對項目投資收益的預計金額,不構成公司對項目投資收益的承諾)。項目的實施將進一步優化公司產品結構,更好地滿足高端市場需要,對公司持續優化產品結構,提升盈利能力,增強核心競爭力,實現持續健康發展具有重要意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.